Does PEMBROLIZUMAB Cause Malignant neoplasm progression? 10,111 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10,111 reports of Malignant neoplasm progression have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 12.1% of all adverse event reports for PEMBROLIZUMAB.
10,111
Reports of Malignant neoplasm progression with PEMBROLIZUMAB
12.1%
of all PEMBROLIZUMAB reports
5,124
Deaths
3,426
Hospitalizations
How Dangerous Is Malignant neoplasm progression From PEMBROLIZUMAB?
Of the 10,111 reports, 5,124 (50.7%) resulted in death, 3,426 (33.9%) required hospitalization, and 610 (6.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 10,111 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
Hypothyroidism (2,326)
What Other Drugs Cause Malignant neoplasm progression?
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
OSIMERTINIB (2,920)
Which PEMBROLIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G